Submit Comments by 02/28/2025 Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment […]

Docket Number: FDA-2022-D-1562 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Center for Biologics Evaluation and Research The Food and Drug Administration (FDA […]

[12-26-2024] The Food and Drug Administration is advising consumers not to purchase or use Lucky Guy Platinum 18000, a product promoted and sold for sexual enhancement […]

[12-26-2024] The Food and Drug Administration is advising consumers not to purchase or use Rhino 69 Gummy, a product promoted and sold for sexual enhancement on […]

It is estimated that over 6.1 million people aged 12 or older have an opioid use disorder (OUD). Medications for opioid use disorder (MOUD) are an […]

Today, FDA issued the Federal Register notice, Modifications to Labeling Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence, to encourage the submission of supplemental new […]

[12-26-2024] The Food and Drug Administration is advising consumers not to purchase or use Rhino Gummy Royal 50000, a product promoted and sold for sexual enhancement […]

[12-26-2024] The Food and Drug Administration is advising consumers not to purchase or use Rhino 11 Gummy, a product promoted and sold for sexual enhancement on […]

Summary Company Announcement Date: December 23, 2024 FDA Publish Date: December 24, 2024 Product Type: Drugs Reason for Announcement: Recall Reason Description Bottles may contain empty […]